VIVEbiotech to Attend the Advanced Therapies Congress 2026 in London
The company will join one of the leading events for the global cell and gene therapy community, showcasing its expertise in GMP lentiviral vector manufacturing.
VIVEbiotech will participate in the Advanced Therapies Congress 2026 organized by Terrapinn, taking place on March 17–18 at ExCeL London. This annual event brings together scientists, industry leaders, and innovators to discuss the latest advancements, trends, and opportunities shaping the future of cell and gene therapy.
Attending on behalf of the company will be Natalia Elizalde (Chief Business Development Officer), Miguel Álvarez (Business Development Manager), and Andrés Lamsfus (Customer Product Development Manager). Throughout the two-day event, they will meet with industry partners, take part in networking sessions, and highlight how VIVEbiotech’s GMP lentiviral vector platform is supporting cutting-edge gene therapy programs worldwide.
Attendees interested in scheduling a meeting with VIVEbiotech in London can do so through the event app via the contact form on the VIVEbiotech website, or by emailing [email protected].
Thank you very much Sartorius.